In exciting publications, Combs et al. showed that PPARγ agonists inhibit the β-amyloid-stimulated expression of the cytokine genes interleukin-6 and tumor necrosis factor α, which brings us closer to the mechanisms of Alzheimer’s disease [81]. The gene discussed is IL6; the disease is early-onset autosomal dominant Alzheimer disease.